EMC Capital Management Makes New $216,000 Investment in Halozyme Therapeutics, Inc. $HALO

EMC Capital Management bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,155 shares of the biopharmaceutical company’s stock, valued at approximately $216,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wealth Preservation Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the first quarter valued at $32,000. SVB Wealth LLC acquired a new stake in Halozyme Therapeutics during the 1st quarter worth about $33,000. Brooklyn Investment Group boosted its position in Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 670 shares during the period. CWM LLC grew its stake in Halozyme Therapeutics by 46.3% during the 1st quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 438 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Halozyme Therapeutics in the 1st quarter valued at about $89,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares in the company, valued at approximately $50,721,994.47. This represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Nicole Labrosse sold 2,227 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the transaction, the chief financial officer directly owned 22,079 shares in the company, valued at approximately $1,721,058.05. This represents a 9.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 110,227 shares of company stock valued at $8,028,955 over the last quarter. Insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

HALO has been the subject of several research reports. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Sunday. JMP Securities increased their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 6th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, October 21st. The Goldman Sachs Group upped their price target on shares of Halozyme Therapeutics from $54.00 to $56.00 and gave the stock a “neutral” rating in a research note on Tuesday. Finally, Benchmark increased their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Seven equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.10.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $70.10 on Wednesday. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The stock has a market capitalization of $8.24 billion, a PE ratio of 16.04, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18. Halozyme Therapeutics, Inc. has a 12-month low of $42.65 and a 12-month high of $79.50. The company has a 50 day moving average price of $70.04 and a two-hundred day moving average price of $63.36.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. During the same quarter last year, the firm earned $1.27 EPS. Halozyme Therapeutics’s revenue for the quarter was up 22.1% on a year-over-year basis. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.